BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 12533265)

  • 21. Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors.
    Lokich J
    Cancer; 2000 Dec; 89(11):2309-14. PubMed ID: 11147602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
    Vassilomanolakis M; Koumakis G; Drufakou S; Aperis G; Demiri M; Barbounis V; Missitzis J; Efremidis AP
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):179-83. PubMed ID: 12647021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
    Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
    Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines.
    Vici P; Di Lauro L; Sergi D; Foggi P; Viola G; Mottolese M; Giotta F; Fattoruso SI; Corsetti S; Giannarelli D; Botti C; Lopez M
    Oncology; 2008; 75(3-4):175-81. PubMed ID: 18841031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines.
    Martí JL; Bueso P; Mayordomo JI; Isla MD; Saenz A; Escudero P; Murillo L; Filipovich E; Andres R; Tres A
    Ann Oncol; 2001 Aug; 12(8):1061-5. PubMed ID: 11583186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
    Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
    Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer.
    Massacesi C; Marcucci F; Boccetti T; Battelli N; Pilone A; Rocchi MB; Bonsignori M
    J Exp Clin Cancer Res; 2005 Mar; 24(1):43-8. PubMed ID: 15943030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel administered on a weekly basis for metastatic breast cancer.
    Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
    J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Vadiaka M; Markopoulos C; Giannopoulos A; Kalahanis N; Stamatiadis D; Kouraklis G; Karatzas G; Liapis C; Syrigos K
    Anticancer Res; 2003; 23(3C):2917-23. PubMed ID: 12926135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab.
    Polyzos A; Kalbakis K; Kentepozidis N; Giassas S; Kalykaki A; Vardakis N; Bozionelou V; Saloustros E; Kontopodis E; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):217-23. PubMed ID: 20922389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study.
    Maisano R; Mare M; Caristi N; Chiofalo G; Picciotto M; Carboni R; Mafodda A; La Torre F
    J Chemother; 2005 Apr; 17(2):242-6. PubMed ID: 15920913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
    Frasci G; Comella P; D'Aiuto G; Thomas R; Capasso I; Elmo M; Botti G; Cortino GR; Lapenta L; De Rosa V; Vallone P; Petrillo A; Comella G
    Ann Oncol; 2000 Mar; 11(3):367-71. PubMed ID: 10811508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?
    Maisano R; Mare M; Zavettieri M; Caristi N; Mesiti M; Scisca C; La Torre F
    Anticancer Res; 2003; 23(2C):1923-6. PubMed ID: 12820480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
    Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.